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ABSTRACT 
BACKGROUND: 
Renal dysfunction is an increasingly recognized co-morbidity among HIV-infected patients on 
HAART. Progression to end stage renal disease impacts negatively on morbidity and mortality. I 
evaluated factors for the development and progression of renal disease, and estimated the 
incidence and prevalence of CKD stage 3 or worse at an HIV clinic in Johannesburg. 
 
METHODS: 
A retrospective study was conducted involving two cohorts of HIV-infected adults on HAART 
attending Themba Lethu Clinic in Johannesburg, South Africa, from June 2010 to May 2012. 
The first cohort, the incident cohort, involved patients initiated on HAART between June 2010 
and May 2012 with normal baseline renal function. The primary outcome from this study cohort 
was doubling of serum creatinine from baseline or development of end stage renal disease. The 
second cohort (prevalent cohort) analysis included HIV-infected patients on HAART during the 
period under study. Patient data was extracted from Therapy Edge, an electronic database. 
 
RESULTS: 
From the incident cohort, 2424 patients met entry criteria, of whom 93 (3.8%) developed renal 
dysfunction after initiation of HAART, with an incidence of acute renal disease and chronic 
kidney disease of 2.9% and 0.9% respectively. A total of 28 (1.2%) patients developed either end 
stage renal disease requiring dialysis or doubled serum creatinine from the baseline. The mean 
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duration for development of end stage renal disease or doubling of serum creatinine was 10.21 
months (range of two weeks to 38 months). 
From the prevalent cohort, 2500 HIV-infected adults met the inclusion criteria, of whom 58 had 
CKD, with a prevalence of 2.3% (95% CI 0.02- 0.03).  
Male sex, hypertension, low body mass index, low CD4 count and TDF based regimen were 
predictors of decline in renal function. 
 
CONCLUSION: 
Doubling of serum creatinine or development of end stage renal disease after initiation of 
HAART was an uncommon finding and the overall incidence and prevalence of chronic kidney 
disease was low. Screening for evidence of renal dysfunction in HIV-infected patients and 
treatment of traditional risk factors for CKD are still important for preventing further renal 
damage.  
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CHAPTER ONE 
1.1 INTRODUCTION AND BACKGROUND OF THE STUDY 
 
Nephropathy is defined as pathological abnormalities or markers of damage, including 
abnormalities in blood or urine tests, or imaging studies1. It has become an important co-
morbidity among Human Immunodeficiency Virus (HIV) infected patients whose presentation 
can be acute renal disease (ARD) or chronic kidney disease (CKD)2. Studies demonstrate that 
African Americans are at greater risk of developing ESRD than their white counterparts in the 
USA3,4. It has been further demonstrated that HIV-associated nephropathy (HIVAN) among 
blacks between the ages of 20 and 64 years is a third leading cause of end stage renal disease4. 
The estimated prevalence of HIVAN is 3.5% among African-Americans living with HIV5. In 
pre-Highly Active Antiretroviral Therapy (HAART) era, HIVAN was characterized by rapid 
deterioration of renal function and ESRD requiring dialysis. With the availability HAART, there 
has been significant reduction in the burden as well as deaths associated with HIV infection6-8. 
 
Tenofovir disoproxil fumarate (TDF) is a widely prescribed antiretroviral medication in patients 
living with HIV with 70% of the patients initiated on TDF based regimen9. In a retrospective 
study conducted between April 2004 and September 2009 in Johannesburg, showed that in 890 
HIV-infected patients initiated on TDF, 21(2.4%) experienced nephrotoxicity {was defined as 
any decline in kidney function from the baseline (acute or chronic) that is secondary to toxins 
including drugs}10. 
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Appropriate management and prompt referral of patients with early renal disease depends on 
identification of renal dysfunction by the physician. Serum creatinine level is routinely used as a 
screening test to assess renal function11-13. However, in clinical trials, ESRD or doubling of 
serum creatinine from baseline, and death are commonly used endpoints14. Doubling of serum 
creatinine is a commonly used endpoint because it reflects a sustained change in renal function, 
and predicts patients who may develop ESRD. It is conveniently used as a surrogate endpoint for 
progression of renal disease14. 
 
I conducted a retrospective cohort study to evaluate risk factors for reaching renal end points 
among HIV-infected patients on HAART at Themba Lethu Clinic (TLC), Helen Joseph Hospital, 
Johannesburg in South Africa. Data was obtained from Therapy Edge, an electronic database.  
The incidence and prevalence of chronic kidney disease was also estimated among HIV-infected 
patients on HAART. 
 
1.2  Problem statement 
  
HIV remains a burden in Southern Africa region, including South Africa. About 6% of people 
living with HIV in South Africa develop chronic kidney disease (CKD)15. Even with HAART, 
CKD remains a problem among patients living with HIV with prevalence varying from 3.3% to 
8.4% according to several studies16-18.  Renal dysfunction can be caused directly by HIV 
infection itself, co-infections, co-morbidities, toxic effects of antiretroviral therapy, or 
opportunistic infections and their treatments as well as other co-morbidities such as hypertension 
and diabetic mellitus19. Progression to ESRD impacts negatively on morbidity and mortality. 
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1.3  Significance of the study 
  
Despite potential benefits of antiretroviral therapy on survival of patients with kidney disease, 
progression to ESRD still occurs20. The ability to predict renal outcome and take appropriate 
interventions such as identifying and screening for CKD among those at risk, and treatment of 
co-morbid conditions may slow the progression of kidney dysfunction and delay the onset of 
renal failure21. 
 
The main aim of the study is to look at the incidence and prevalence of CKD stage 3 or worse in 
HIV infected patients on HAART, and evaluate risk factors associated with the development of 
renal disease. 
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1.4 LITERATURE REVIEW 
 
1.4.1 HIV Burden  
 
At the end of 2010, about 34 million people were living with HIV worldwide, which represents 
an increase of 17% from 200122. Majority of these HIV-infected patients (68%) were living in 
sub-Saharan Africa22.  
 
In South Africa, the estimated total number of HIV-infected patients increased from 4.1 million 
in 2001 to 5.24 million by 2010 representing 10.5% of the total population23. The estimated 
prevalence of HIV in Gauteng province is 10.3%24. Among all the provinces, Gauteng has the 
fifth largest number of people living with HIV after Kwazulu Natal, Mpumalanga, the Free State 
and North West provinces24. Over 1 million people living with HIV are estimated to be on  
HAART in South Africa with Gauteng province having the second largest number of patients on 
HAART, with over 207,000 estimated to be treated at various sites by end of  March 201025. 
 
1.4.2 HIV infection and kidney disease 
 
HIV infected patients are at risk of developing either acute renal dysfunction or CKD. In 
assessing patients with renal dysfunction, it is important to distinguish acute kidney disease from 
chronic kidney disease as this may have an impact on management.  
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1.4.2.1 Acute kidney disease (AKD) 
 
AKD is defined as acute kidney injury (AKI) or GFR<60ml/min per 1.73m2 for <3 months or 
decrease in GFR by >35% or increase in serum creatinine by >50% for < 3months or structural 
kidney damage for <3months26. While AKI is defined as an abrupt (within 48 hours) reduction in 
kidney function  based on an elevation in serum creatinine level, a reduction in urine output, the 
need for renal replacement therapy (dialysis), or a combination of these factors27.  
 
AKI is a common finding among people living with HIV and is associated with advanced stages 
of HIV infection as well as traditional risk factors for AKI, such as old age, diabetes, pre-existing 
CKD and hepatitis co-infection28,29. In a prospective study conducted among 754 ambulatory 
HIV-infected patients, of whom 61% were blacks, reported an incident rate of acute kidney 
injury of 5.9 per 100 person-years29. However, in hospitalized patients, an incidence of 14.8% 
has been reported among HIV-infected patients using RIFLE criteria for AKI, a decline from 
18% as previously reported30, 31.  
 
In 2004, the Acute Dialysis Quality Initiative (ADQI) workgroup developed a classification 
system for AKI abbreviated RIFLE (Risk of renal dysfunction, Injury to the kidney, Failure or 
Loss of kidney function, and End-stage kidney disease) as shown in Table 1.132. RIFLE is 
increasingly used in research32. 
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Table 1.1: Classification for acute kidney injury (AKI) using RIFLE criteria 
 
Category GFR Criteria Urine Output (UO) Criteria 
Risk Increased creatinine x1.5 or GFR decrease 
> 25% 
Urine output < 0.5ml/kg/h x 6 hr 
Injury Increased creatinine x2 or GFR decrease > 
50% 
Urine output < 0.5ml/kg/h x 12 hr   
Failure Increase creatinine x3 or GFR decrease > 
75% 
Urine output < 0.3ml/kg/h x 24 hr 
or Anuria x 12 hrs 
Loss Persistent ARF = complete loss of kidney function > 4 weeks 
ESRD End Stage Renal Disease (> 3 months) 
 
ARF, Acute Renal Failure. 
 
1.4.2.2 Chronic Kidney Disease (CKD) 
 
CKD is defined as abnormalities of kidney structure or function, present for >3 months, with  
implications for health26. Criteria for definition of CKD according to 2012 KDIGO guidelines is 
as shown below in Table 1.2. 
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Table 1.2: Criteria for CKD (either of the following present for >3 months) 
 
Markers of kidney damage (one or more) Albuminuria (AER >30 mg/24 hours; ACR >30 
mg/g [≥3 mg/mmol]) 
Urine sediment abnormalities 
Electrolyte and other abnormalities due to tubular 
disorders 
Abnormalities detected by histology 
Structural abnormalities detected by imaging 
History of kidney transplantation 
Decreased GFR GFR <60 ml/min/1.73 m2 
 
The US National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (K/DOQI) 
published its classification of five stages of chronic kidney disease based on GFR in table 1.333: 
 
Table 1.3: Stages of CKD 
 
Stage  Description  GFR (mL/min/1.73 m2) 
1 Kidney damage with normal or 
increased GFR 
 >90 
2 Mild reduction in GFR  60-89 
3 Moderate reduction in GFR  30-59 
4 Severe reduction in GFR  15-29 
5 Kidney failure  < 15 or dialysis 
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1.4.3 HIV- related CKD burden in Africa 
 
Unlike in developed countries, chronic kidney disease is 3–4 times more common in Africa34.  
CKD is among the important potential chronic complication of HIV in sub-Saharan Africa35.   
Studies have also demonstrated that HIV-associated nephropathy (HIVAN) is more common 
among HIV-infected patients of African descent36.   
 
1.4.3.1 Apolipoprotein L1 (APOL 1) and risk 
 
Studies have identified specific genetic variants within the APOL1 gene as a major contributor to 
these ethnic differences, rather than MYH9 gene on chromosome 22 as previously thought37,38. 
The G1 and G2 variants of APOL 1 are predominately found in people of African descent38. 
Studies show that these variants are believed to be responsible for the disparities in rates of 
ESRD observed between black patients and white patients38,39.  
  
The APOL 1 variants are fatal to Trypanosoma brucei rhodesiense, a parasite that causes African 
sleeping sickness, conferring a survival advantage to carriers40. Thus there is an increased 
prevalence of these variants in affected populations (predominately in Southern and East Africa). 
 
APOL1 normally cause glomerulosclerosis by various mechanisms41. It associates with high-
density lipoprotein (HDL) particles in the circulation, and the APOL 1 variants may bind less 
tightly to the circulating HDL, undergo glomerular filtration and proximal tubular resorption, 
thereby causing kidney disease. Renal disease may also be caused by circulating APOL1 variant 
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proteins, either free in circulation or bound to HDL which may be filtered by the kidney42. 
Endogenous APOL1 in the renal epithelium-like cell may cause apoptosis or autophagic cell 
death43. APOL1 variants have the capacity to induce podocyte injury which is further augmented 
by adverse host factors such as hydrogen peroxide, hypoxia, tumour necrosis factor-α, and 
puromycin aminonucleoside44. HIV-1 infected cells release cytokines such as IFN-γ and TNF- α 
that promote APOL-1 expression in endothelial cells45.  
 
Studies demonstrate that the absence of risk alleles strongly predicts lesions other than Focal 
Segmental Glomerulosclerosis (FSGS). About 76% of those with biopsy-proven FSGS carried 
two risk alleles46. However, there is no direct role of the APOL1 risk variants in the pathogenesis 
of HIV-associated immune complex glomerulonephritis46. 
 
1.4.3.2 Other risk factors 
 
This racial predilection for ESRD in HIV infection is consistent with the epidemiology of ESRD 
in the general population, for which the risk of progression from CKD to ESRD has been 
reported as 4-fold higher in blacks compared with whites47. The risk of ESRD in persons infected 
with HIV appears to be due to traditional risk factors associated with CKD such as hypertension, 
cardiovascular disease, diabetes, dyslipidaemia, as well as HIV disease severity48. Markers of 
HIV disease severity include a CD4 cell count of less than 200 cells/µL and a high viral 
burden48. A retrospective study of 22,156 people living with HIV without pre-existing ESRD 
showed that patients with low CD4 counts (less than 200 cells/µL) incurred a 50% increase in 
10 
 
ESRD risk, whereas those with CD4 lymphocyte counts of 200-350 cells/µL did not have 
increased risk48. Similarly, having a HIV viral load of more than 30,000 copies/mL, hepatitis C 
co-infection or hypoalbuminemia each were associated with a 2-fold increase in ESRD risk48.  
 
1.4.4 HIVAN 
 
In pre-HAART era, HIVAN was characterized by acute deterioration of kidney failure and end 
stage renal disease requiring dialysis. Antiretroviral therapy has reduced the morbidity and 
mortality associated with HIV infection, as well as leading to a substantial decline in 
HIVAN49,50.  
 
A case study of a 28 years old HIV-1 positive African American with HIVAN requiring 
haemodialysis showed that a few months after starting HAART, dialysis was not required, and 
serum creatinine and proteinuria improved51. 
 
HIVAN is characterized by worsening renal disease, usually associated with proteinuria and 
enlarged, echogenic kidneys on ultrasound scan52.The pathogenesis of HIVAN may be due to 
direct HIV-1 infection of epithelial cells in the kidneys with resultant expression of nef and vpr 
genes which induce podocyte dysfunction and apoptosis of renal epithelial cells in genetically 
predisposed individuals53,54. In HIVAN, podocytes exhibit a dysregulated phenotype {loss of 
regulatory protein Wills tumor-1 (WT-1)} characterized by increased proliferation, apoptosis and 
dedifferentiation53,54,55. Podocytes in HIVAN also have reduced expression of synaptopodin and 
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WT-1 while the expression of desmin, which forms part of intermediate filaments is increased. 
The expression of WT-1 down-regulates proliferation56. 
 
The commonest histological finding in HIVAN is a collapsing variant of FSGS 57,58. Diagnosis of 
HIVAN is based on the presence of the following typical features on renal biopsy; focal 
segmental glomerulosclerosis in its collapsing variant, absence of immune deposit by 
immunofluorescence and tubules with microcystic changes and proteinaceous casts in the 
lumen58. However, HIV seropositive individuals may present with a variety of other glomerular 
lesions such as arterionephrosclerosis, pyelonephritis, interstitial nephritis, diabetic nephropathy, 
IgA nephropathy, cryoglobulinemia, amyloidosis, a lupus like immune complex glomerulopathy 
and HIV-associated thrombotic microangiopathy 58, 59,60. 
 
Renal biopsy is required for differentiating HIVAN from other diseases responsible for kidney 
disease. Indications for renal biopsy in patients with HIV infection may include significant 
proteinuria, evidence of progressive disease, unexplained acute renal failure or an acute nephritic 
syndrome61. 
 
1.4.5 Effects of drugs on renal function 
 
1.4.5.1 HAART 
 
HAART has resulted in significant decline in HIVAN, however, HAART may directly induce 
for kidney dysfunction62. Most of these drugs are metabolized and excreted by the kidney. 
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Studies have shown that major predictors of eGFR decline in patients on HAART are 
hypertension, hyperlipidaemia, proteinuria, use of tenofovir or stavudine and higher viral load63. 
Several antiretrovirals are associated with renal dysfunction thus it is important to monitor renal 
function and adjust the dosage based on eGFR. 
 
The South African Antiretroviral Treatment Guidelines of 2010 and those updated in 2013,  
recommend the use of a combination of three antiretroviral agents which including 
nucleoside/nucleotide reverse transcriptase inhibitors and a non nucleoside reverse transcriptase 
inhibitor as a first line regimen or two reverse transcriptase inhibitors plus protease inhibitor as 
second line64,65. TDF nephrotoxicity predominantly occurs in patients with underlying kidney 
disease, the elderly, with prolonged use, an elevated baseline creatinine, African American 
ethnicity, CD4 <200cells/µL and concomitant administration of nephrotoxic drugs66. 
 
If TDF is combined with protease inhibitors such as lopinavir/ritonavir the risk of renal toxicity 
increases. Protease inhibitors indirectly cause renal toxicity by increasing TDF concentrations in 
plasma and renal tubular epithelium, thereby increasing the risk of TDF toxicity, because they 
decrease renal clearance of TDF by 17.5%, by inhibiting its transport across renal tubules67,68. 
Patients with low-body weight may have high TDF concentrations, therefore they are at 
increased risk of kidney impairment69. The most common manifestation of TDF nephrotoxicity 
is proximal tubular dysfunction, sometimes causing Fanconi’s syndrome which is characterized 
by proximal tubular acidosis, hypophosphatemia, hypouricemia, glycosuria in absence of 
hyperglycemia, and proteinuria69.  
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Diagnostic criteria of TDF nephrotoxicity are based on evidence of TDF use at the time of 
presentation, histological findings of mitochondrial tubulopathy, an acute renal dysfunction 
without alternative causes of acute decline in renal function70. The outcome after discontinuation 
of TDF is good, however, a small number of patients continue to have impaired renal function 
for more than 6 months after TDF discontinuation71.  
 
1.4.5.2 Other drugs 
 
Several non-antiretroviral drugs such as amphotericin B, pentamidine and acyclovir, may cause 
renal toxicity 72. These drugs are usually used in the treatment of opportunistic infections. 
 
1.4.6 Screening for renal disease 
 
The importance of prevention of CKD in HIV-infected individuals should not be underestimated. 
Screening for renal diseases in HIV infected individuals has been recommended in high risk 
groups for CKD such as individuals of black ethnicity, those with diabetes, hypertension, 
hepatitis C virus co-infection, CD4 cell counts less than 200 cells/mm3, or HIV RNA levels 
greater than 4000 copies/Ml73. Baseline screening tests at initial HIV documentation may include 
urine analysis for proteinuria, serum creatinine with eGFR73. If baseline screening tests are 
abnormal, then further investigations such as urine protein-creatinine ratio (urine PCR) and renal 
ultrasound should be performed. Those who are at risk of developing CKD with normal baseline 
screening tests should be rescreened annually73.  
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1.4.6.1 Determining GFR 
 
The gold standard methods for determining GFR include inulin and iothalamate clearance (IC), 
but these tests are expensive, time-consuming, highly dependent on collection accuracy and thus 
not routinely performed in clinical practice74,75. Serum creatinine concentration is the most 
frequently used test of renal function because of its availability and affordability. Furthermore, 
creatinine clearance (CrCl) or eGFR can be easily estimated from serum creatinine levels and 
other variables76. However, serum creatinine is not a reliable estimate of GFR because its 
concentration is affected by several factors such as age, weight, muscle mass, race, various 
medications and extraglomerular elimination. Studies demonstrate that among patients with 
creatinine levels within normal range, between 11.6% (108 out of 928 patients) and 15.2% (387 
out of 2543 patients) were found to have decreased GFR77-80. 
 
In clinical practice, creatinine-based equations, such as the Cockcroft-Gault (CG), the 
Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equations are commonly used to evaluate kidney function81-83. 
Halving of GFR assessed as doubling of creatinine level has been accepted by The US Food and 
Drug Administration as a surrogate endpoint for development of kidney failure84. Halving of 
kidney function sustained over a period of time will likely proceed to dialysis or renal 
transplantation and thus is felt to reflect a sustained reduction in GFR and hence progression to 
ESRD85 86. 
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1.4.7 Conclusion 
 
Renal disease is an important co-morbid condition among HIV-infected patients. It occurs in a 
wide clinical spectrum which includes potentially reversible AKD and CKD. Causes of 
nephropathy are diverse and usually multifactorial. Several factors are associated with renal 
disease which include traditional risk factors for CKD, HIV disease severity, HAART and 
nephrotoxic drug use. In post HAART era, there has been reduction in morbidity and mortality 
associated with HIV infection as well as reduction in HIVAN. A variety of glomerular lesions 
may be found on histological examination but HIVAN remains common among black 
Africans87,88. Measurements of proteinuria and eGFR are important in assessing renal function. 
In clinical trials doubling of serum creatinine, ESRD, and death are commonly used end points. 
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CHAPTER TWO 
2.1 OBJECTIVES 
 2.1.1 Broad objective 
To evaluate the relevance of defined variables that may be associated with the development and 
progression of renal disease in HIV-infected individuals on HAART attending Themba Lethu 
Clinic in Johannesburg from June 2010 to May 2012. 
 
2.1.2 Specific objectives 
1. To evaluate factors associated with doubling of serum creatinine as a marker of significant 
renal damage or the development of end stage renal disease in HIV-infected patients on HAART. 
 
 2. To determine the mean duration for doubling of serum creatinine or developing end stage 
renal disease. 
 
3. Describe the incidence and prevalence of CKD stage 3 or worse in HIV-infected patients on 
HAART at an HIV clinic in Johannesburg. 
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2.2 RESEARCH DESIGN AND METHODOLOGY 
2.2.1 Population and study sample 
 
This was a retrospective cross-sectional study conducted at Themba Lethu Clinic (TLC). TLC is 
the biggest government antiretroviral treatment site in South Africa. The clinic is situated at 
Helen Joseph Hospital in Johannesburg. About 30,000 HIV-infected patients have been enrolled 
into the HIV care and treatment programme since its inception in April 2004, with over 21,000 
patients initiated on HAART9. The majority of the cohort at the clinic are of African ethnicity 
(93%) and are predominately female (64%)9.  
 
TLC follows the National HAART Treatment Guidelines. Patients are seen at least every 3 
months. Serum creatinine level is taken at baseline, three months, six months then yearly if the 
patient is on TDF, so as to detect TDF toxicity. Data fields collected routinely at TLC include 
demographic, clinical visit, laboratory, medication and clinical data as shown in Table 2.19. 
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Table 2.1: Data fields collected routinely on patients at TLC 
 
 
2.2.2 Study population 
 
In this study, about 5,000 HIV-infected persons on HAART attending TLC between June 2010 
and May 2012 were targeted. The study population was divided into incident and prevalent 
cohorts. Patients were screened from the data base to identify those with documented HAART 
use. The target for each cohort was 2,500 HIV- infected patients. 
Data fields Variable list 
Demographics Name, national ID number, contact details, 
gender, date of birth, employment status, 
alcohol use, smoking history, ethnicity and 
education level 
Clinical visit data Date of visit (scheduled and actual), TB 
screening, urine analysis, vital signs, height, 
weight, description and duration of new 
symptoms and systems-based clinical 
examination 
(e.g. cardiology, neurology, and respiratory) 
Laboratory results ART initiation and monitoring bloods, 
including CD4 count, HIV viral load, full 
blood counts, liver function tests, renal 
function tests, TB microscopy and culture 
results, lactate levels and glucose and lipid 
profiles 
Medication history Date of start and stop of ART and non-ART 
medications, reasons for treatment 
discontinuation and self-reported treatment 
adherence 
Clinical diagnoses Pregnancy, opportunistic infections including 
TB, hepatitis, PCP, AIDS-related 
malignancies including Kaposi sarcoma, 
ART toxicities including peripheral 
neuropathy, anaemia, hyperlactataemia/ 
lactic acidosis and lipoatrophy 
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2.2.2.1 Incident cohort 
 
These patients were initiated on ART between June 2010 and May 2012, were greater than 18 
years of age, had documented baseline weight, height, CD4 count and serum creatinine recorded 
prior to initiation of HAART and had been followed up at the clinic after initiation of HAART 
with laboratory monitoring of renal function for at least 6 months. These patients had normal 
renal function (eGFR >60 mL/min/1.73 m2 at initiation of HAART). Patients with missing 
demographic information and baseline blood tests were excluded from the study. 
 
On each patient, the following information was obtained; gender, age, ethnicity, body mass 
index, blood pressure and concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), 
amphotericin B, acyclovir, aminoglycosides and ACE inhibitors which may be potentially 
nephrotoxic drugs. The use of antiretroviral medications such as tenofovir based regime with or 
without protease inhibitors including other regimens were recorded. Laboratory data including 
serum creatinine, eGFR was obtained (Appendix 1).  
 
2.2.2.2 Prevalent cohort 
 
To describe the burden of CKD, 2500 patients who were on antiretroviral therapy during the 
period under study (regardless of when they were started on HAART) were targeted. This 
included patients who were initiated on HAART before June, 2010 and those who were started 
on HAART between June 2010 and May 2012. The baseline demographic information obtained 
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included sex, age, race as well as BMI. Two consecutive measures of eGFR taken at least three 
months apart were obtained (Appendix 2). 
 
2.3 Data Sources and Management 
 
Patient data was extracted from Therapy Edge, an electronic database after fulfilling the Clinical 
HIV Research Unit (CHRU) Standard Operating Procedure (SOP). Data was managed using 
Excel and SPSS. 
 
2.4 Definition of Study Variables 
 
i) Hypertension: 
 Was defined as blood pressure greater than 140/90 mmHg on three separate occasions89, 
or use of antihypertensive medications. 
 
ii) TDF based regimen was defined by documentary evidence of TDF use, while TDF use with 
protease inhibitor was defined as use of TDF with either indinavir or lopinavir/ritonavir. 
 
iii) Nephrotoxic drug use was defined as documented use of NSAID, amphotericin B, acyclovir, 
aminoglycosides and/or ACE (angiotensin-converting-enzyme) inhibitors. 
iv) Gender was defined as male or female. 
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v) Body mass index (BMI): Was calculated as weight in kilograms divided by the square of 
height in meters: underweight, normal weight, and overweight were defined as BMI less than 
18.50kg/m2, BMI between 18.5kg/m2- 24.99kg/m2 and BMI ≥25.0kg/m2 respectively. 
 
vi) Elderly was defined as patients greater than 65 years of age. 
 
vii)  Ethnicity was defined as black or other races. 
 
viii) High viral load was be defined as viral load >30,000 copies/ml48. 
 
ix) CD4 count nadir was defined as CD4 count less than 200 cells/µL29. 
 
x) Doubling of serum creatinine was defined as two fold increase in serum creatinine from 
baseline. 
 
xi) Normal renal function was based on eGFR >60 ml/min per 1.73 m2. 
 
xii) Acute Kidney Disease (AKD) was defined as GFR <60 ml/min per 1.73 m2 for <3 months26. 
 
xiii) CKD stage 3 or worse was defined as two consecutive measures of GFR <60 ml/min per 
1.73 m2 over ≥ 3 months.  
 
xiv) ESRD was defined as CKD stage 5. 
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2.5 Evaluation of renal function 
 
Renal function was evaluated using serum creatinine and eGFR. eGFR was  calculated by using 
4-variable Modification of Diet in Renal Disease (MDRD) formula as shown below81: 
 
eGFR (ml/min/1.73 m2) = 175 × {[plasma creatinine (µmol/l) / 88.4] −1.154} × age (years) −0.203 × 
0.742 (if female). 
 
 2.6 CKD 
 
Patients with eGFR of less than 60 ml/min/1.73 m2 were categorised as having renal dysfunction 
while measurement of eGFR over a 3-month or greater period was used to establish CKD stage 3 
or worse. At least two consecutive readings of eGFR 3 or months apart were used to define CKD 
in prevalent population. Proteinuria is a marker of progression of CKD. It can be evaluated by 
measurement of urine albumin-to-creatinine ratio (ACR) and urine protein-to-creatinine ratio 
(PCR)26. 
  
2.7 Variable Outcome 
 
The primary variable outcome was doubling of serum creatinine from the baseline, or 
development of end stage renal disease (ESRD). Trends were analysed from their baseline serum 
creatinine before initiation of antiretroviral therapy. Doubling of serum creatinine was defined as 
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a twofold increase in serum creatinine concentration from baseline while ESRD was defined as 
CKD stage 5. 
 
2.8 Statistical Analysis 
 
Statistical analysis included descriptive, bivariate and multivariate analyses. Characteristics of all 
laboratory tests done were entered in excel sheet as well as patients’ demographic characteristics, 
nephrotoxic drugs and HAART regime.  
To measure the association between explanatory variables and outcome variable for categorical 
values, Pearson Chi-Square and Fisher’s Exact Test were used for analysis. Binary linear logistic 
regression was used to establish the risk associated with defined variables to development of 
variable outcome. A value of p<0.05 was set to be statistically significant with confidence 
interval of 95%. All p-values were two tailed. 
 
Population data for the period under study constituted the denominator for CKD incidence and 
prevalence estimations. For numerators new cases, and new and old cases, were used to calculate 
incidence and prevalence respectively. Analysis was performed using SPSS statistics 19. 
 
2.9 Ethical Consideration 
 
Ethical clearance to conduct the study was obtained from the Human Research Ethics Committee 
(Medical) of University of the Witwatersrand (Appendix 3). Permission to conduct the study was 
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also sought from the Regulatory Manager at the CHRU, Department of Internal Medicine, Helen 
Joseph Hospital (Appendix 4). Patients were not directly involved in the study as data was 
obtained from an electronic data base. Confidentiality was respected as no patient identifiers 
were used in data collection, analysis and reporting. 
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CHAPTER THREE 
3.0 RESULTS 
 
3.1 Incident cohort 
 
A total of 2,424 out of 2,500 HIV-infected patients who were started on HAART between June 
2010 and May 2012 were included for study analysis, 76 patients did not meet inclusion criteria 
for the study because they were either missing baseline information or had impaired renal 
function prior to initiation of HAART.  There were 1,564 females (64.5%), the median age was 
36.8years (range 18 – 69years) years with majority of the patients being Africans (black) 
(94.9%), Table 3.1. 
 
Among patients with recorded BMI, 10.6% were underweight, 41.5% had normal weight while 
24.3% were overweight with BMI of < 18.5kg/m2, 18.5kg/m2 to 24.9kg/m2 and > 25kg/m2 
respectively. 
TDF based regimen was the commonly prescribed first line regimen at initiation (76.5%). 
Among the study cohort, 68.1% had a CD4 nadir of <200 cells/ µL at initiation but only 3% of 
the patients had their viral load test done prior to initiation of HAART.  
The proportion of hypertensive patients among this study group was 23.7%. Only 6.5% of the 
patients were recorded as having a history of nephrotoxic drugs use.  
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Of 2,424 patients with normal baseline renal function, 93 (3.8%) developed renal dysfunction 
(eGFR less than 60 ml/min/1.73m2 based on eGFR estimation using MDRD equation) after 
initiation of HAART. Of 93 patients with renal dysfunction, 70 (2.9%) developed ARD after 
initiation of HAART while 23 developed CKD stage 3 or worse, representing an incidence of 
0.9% (Figure 1).  
Across the entire cohort, 28 (1.2%) developed either ESRD or doubled serum creatinine from the 
baseline after initiation of HAART. When these data were stratified for the use of a specific 
antiretroviral, there was strong correlation between doubling of serum creatinine and use of a 
tenofovir based regimen (p=0.039). Patients with a low BMI were more likely to double serum 
creatinine than those with normal weight (p=0.012). There was also a positive correlation 
between CD4 count and development of ESRD or doubling of serum creatinine with a p= 0.044. 
There was no significant relationship between sex, hypertension, the use of nephrotoxic drugs, 
and the development of ESRD or doubling of serum creatinine.  
 
Proteinuria is an important marker of kidney disease, but this was not recorded in the data base at 
the clinic therefore no results were available for analysis. 
Significant variables were further analysed using a linear logistic regression model as shown in 
Table 3.2. 
 
The mean duration for the development of ESRD or doubling of serum creatinine was 10.21 
months with a range of two weeks to 38 months. 
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Table 3.1: Incidence cohort showing baseline characteristics and bivariate analysis of factors associated with renal 
                  dysfunction and doubling of serum creatinine or development of end stage renal disease 
 Frequency Bivariate 
 
Characteristic 
 
n1 = 2424 
Renal dysfunction ESRD or Doubling of serum 
creatinine 
n2=93 
(3.8%) 
p-value n3=28 (1.2%) p-value 
Demographics 
Sex 
 
Female 1564 (64.5%) 47 
 
0.004 
15 
 
0.223 Male 860 (35.5%) 46 13 
Race Black African 2301 (94.9%) 90 
 
0.627 
27 
 
1.000 Other races 123 (5.1%) 3 1 
Age in years Median 36.8(range 18.2- 
69) 
  
 
 
0.068 
  
 
 
1.000 
< 65 2399 (99.0%) 90 28 
≥ 65 25 (1.0%) 3 0 
HIV related factors 
HAART Regimen 1 (TDF based) 1855 (76.5%) 65 
 
 
 
 
0.455 
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0.039 
2(TDF+ Lopinavir) 54 (2.2%) 3 0 
3 (Lopinavir with 
other) 
32 (1.3%) 2 2 
4 (other) 483 (19.9%) 23 4 
CD4  nadir at initiation of 
HAART(cells/uL) 
< 200 1651 (68.1%) 78 
 
0.001 
24 
 
0.044 ≥ 200 773 (31.9%) 15 4 
Viral load at initiation  of 
HAART (copies/ml) 
≥ 30,000 72 (3%) 3 
 
 
0.815 
1 
 
 
1.000 
< 30,000 5 (0.2%) 0 0 
Missing 2347 (96.8%) 90 27 
28 
 
 
Table 3.1: (Continued) 
 
n1, total number of HIV infected patients on HAART 
n2, renal dysfunction after initiation on HAART 
n3, Variable outcome, doubling of serum creatinine or development of end stage renal disease 
 
 Frequency Bivariate 
 
Characteristic 
 
n1 = 2424 
Renal dysfunction ESRD or Doubling of serum 
creatinine 
n2=93 
(3.8%) 
p-value n3=28 (1.2%) p-value 
Concurrent medical conditions and drug use 
 
Baseline BMI(kg/m2) 
<18.5 
(underweight) 
257 (10.6%) 11 
 
 
 
 
 
 
0.931 
6 
 
 
 
 
 
0.012 
18.5to24.9 
(normal) 
1007 (41.5%) 40 12 
>25.0 
(overweight) 
588 (24.3%) 22 1 
Missing 572 (23.6%) 20 9 
Hypertension Yes 574 (23.7%) 34 
 
0.005 
8 
 
0.593 No 1791(73.9%) 59 20 
No 521 (90.8%) 31 6 
Nephrotoxic  use Yes 157 (6.5%) 7 
 
0.675 
2 
 
0.702 No 2267 (93.5%) 86 26 
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Figure 1:  Flow diagram of incident cohort  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2424 patients (Incident cohort) with 
normal renal function (eGFR > 
60ml/min/1.73m
2
) before initiation of 
HAART. 
93 patients with renal dysfunction 
after initiation of HAART (eGFR < 
60ml/min/1.73m
2
). 
 
2331 patients with normal 
renal function after initiation 
of HAART (eGFR > 
60ml/min/1.73m
2
). 
23 patients with chronic 
kidney disease (CKD). 
 
70 patients with acute 
kidney disease (AKD). 
 
28 patients with either 
ESRD or doubling of 
serum creatinine from 
the baseline. 
30 
 
Table 3.2: Incident cohort showing Multivariate logistic regression of explanatory variables     
associated with doubling of serum creatinine or development of end stage renal disease. 
 
Variable Odds ratio 95% confidence interval 
HAART Regimen 
CD4 <200 cells/uL 
0.989 
2.825 
0.715-1.369 
0.771-8.218 
HAART Regimen 
Baseline BMI 
1.215 
0.358 
0.850-1.737 
0.176-0.727 
Baseline BMI 
CD4 <200 cells/uL 
0.376 
2.910 
0.184-0.768 
0.665-12.727 
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3.2 Prevalent Cohort 
 
Of the 2,500 HIV-infected patients on HAART, the median age was 36.3years (range: 18 – 
70years), 66.9% were female, 97% were black African, were included for analysis as shown in 
Table 3.3. 
The results show that 34.5% of the patients were on TDF based regimen lower than the incident 
group (76.5%). Among patients with a recorded BMI, 12.3% were underweight, 48.2% had 
normal weight while 23.6% were overweight 
Across the cohort, 58 patients had CKD stage 3 or worse representing a prevalence of 2.3% 
(95% CI 0.02 - 0.03). 
Of all patients with CKD stage 3 or worse, 44 (75.9%) had a moderate reduction in eGFR (30-59 
mL/min/1.73 m2), 8 (13.8%) had a severe reduction in Egfr (15-29 mL/min/1.73 m2) and 6 
(10.3%) had ESRD (eGFR less than 15 mL/min/1.73 m2) as shown in Figure 2. 
Similarly to the incident cohort, there was unfortunately no recording of proteinuria in the TLC 
database. 
In multivariate model, the risk factor for CKD were TDF based regimen and low BMI (Table 
3.4).   
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Table 3.3:  Prevalent cohort showing baseline characteristics of CKD stage 3 or worse 
 
 
 
 
 
VARIABLE Number (n=2500) CKD 
n=58 (2.3%) 
CKD stage 
3 4 5 
Sex 
 
Female 1672 (66.9%) 23 19 2 2 
Male 828 (33.1) 35 25 6 4 
Ethnicity Black or African 2424 (97%) 51 43 8 6 
Other races 76 (3.0%) 1 1 0 0 
HAART Regimen 1 (TDF based) 862 (34.5%) 5 5 0 0 
2 (TDF + Lopinavir) 35 (1.4%) 1 1 0 0 
3 (Lopinavir with other) 104 (4.2%) 0 0 0 0 
4 (other) 1499 (60%) 52 38 8 6 
Baseline BMI(kg/m2) < 18.5 (under weight) 307 (12.3%) 11 7 4 0 
18.5 to < 25.0 (normal) 1204 (48.2%) 21 16 3 2 
≥ 25.0 (overweight) 589 (23.6%) 16 14 1 1 
Missing 400 (16%) 10 - - - 
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Table 3.4: Prevalent cohort showing multivariate logistic regression of factors associated with 
CKD stage 3 or worse in the prevalent cohort 
 
Variable Odds ratio 95% confidence 
interval 
p-value 
HAART Regimen 
Body Mass Index (BMI) 
1.981 
0.978 
1.384-2.835 
0.623-1.535 
<0.05 
0.92 
Body Mass Index (BMI) 
Sex 
1.182 
3.608 
0.737-1.895 
1.958-6.645 
<0.05 
<0.05 
Sex 
HAART Regimen 
3.378 
1.877 
1.977-5.771 
1.386-2.542 
<0.05 
<0.05 
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CHAPTER FOUR 
4.1 DISCUSSION 
4.1.1 Incident cohort 
 
The important endpoint of this study was doubling of serum creatinine or development of ESRD. 
From this study cohort, ESRD or doubling of serum creatinine after initiation of antiretroviral 
therapy was infrequent. Factors associated with doubling of serum creatinine or development of 
ESRD in HIV-infected patients initiated on HAART included CD4 nadir <200 cells/uL, TDF 
based regimen and low body mass index. 
Regarding lower CD4 nadir count, the study findings were consistent with other studies showing 
that HIV-patients with low CD4 are at more risk of developing kidney disease independent of 
other risk factors48. Early diagnosis and treatment of HIV-infected patients would avoid 
occurrence of low CD4 counts thus possibly preventing additional kidney disease. 
High viral load, a marker of advanced HIV disease, is associated with an increased risk of renal 
dysfunction48. However, in this study, there was no significant difference in doubling of serum 
creatinine or development of ESRD among individuals with viral load > 30,000copies /ml or 
<30,000 copies/ml. The possible reason for this may be explained by fewer patients 77 (3.2%) 
who had a viral load test done prior to initiation of HAART. 
This study showed no significant difference in the development of ESRD or doubling of serum 
creatinine among HIV-infected patients older or younger than 65 years. This is in contrast with 
other studies that have demonstrated that old age is a risk factor for the development of renal 
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dysfunction66. This inconsistent finding may be attributed to the fact that my study cohort was 
predominately younger than 65 years of age with only 1% of the cohort older than 65years.  
The study findings showed that was no difference in development of ESRD or doubling of serum 
creatinine with respect to patient ethnicity, however the cohort was predominantly of black 
African origin. This is in contrast to the data reported from other studies that demonstrated that 
CKD in people living with HIV is more prevalent in black populations and are more likely to 
progress to ESRD36,47. 
 The study findings show that there was a statistical difference in patients with hypertension and 
those who developed renal dysfunction which was consistent to other reported data63. However, 
there was no association between hypertension and ESRD or doubling of serum creatinine from 
baseline. 
The findings of this study demonstrate that there was strong correlation between doubling of 
serum creatinine or development of ESRD and TDF based regimen which was consistent to other 
reported data that decline in renal function was associated with TDF use10,62. However, studies 
show that discontinuation of TDF may lead to recovery of renal dysfunction10, 71. In a study 
conducted predominantly among Caucasians and African Americans, showed that the female 
gender, black race, and a CD4 count of <200 cells/uL were factors associated with renal 
dysfunction after initiation of tenofovir57. It was noted that the use of nephrotoxic drugs was not 
significantly correlated with doubling of serum creatinine or development of ESRD. This is 
discordant with other studies that demonstrated that use of nephrotoxic drugs or therapy factors 
are related to decline in eGFR72.  
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The mean duration for doubling of serum creatinine or development of ESRD was 10.2 months 
with a range of two weeks to 38 months. Studies have shown that more than 50% of patients 
develop acute renal disease within three months after commencement of HIV care (such as 
antiretroviral therapy and prophylaxis against opportunistic infections) and incidence of AKD 
decreased more than 10-fold in patients who had been on HIV care for more than three months90. 
This demonstrates that HIV-infected patients are at risk of developing renal dysfunction 
regardless of the duration they have been on HAART. 
 
Out of the 2,424 patients with normal baseline renal function, 93(3.8%) developed renal 
dysfunction (defined as GFR < 60ml/mim/1.73m2) after starting HAART with an incidence of 
AKD of 2.9%. This is lower than 14.8% reported in hospitalized HIV-infected patients30. This 
was expected as hospitalized patients are more likely to have other co-morbidities that may 
contribute to renal dysfunction. The findings of the study showed that male sex, low CD4 and 
hypertension were predictors of renal dysfunction which is consistent with data reported from 
other studies 26,28,91. 
.  
The incidence of CKD stage 3 or worse among incident cohort was 0.9%. The incidence of CKD 
was low which was consistent with that found in other studies (1.5 per 100 person years and 1.45 
per 100 person years)92,93.  
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4.1.2 Prevalent cohort  
 
The prevalence of CKD stage 3 and among the prevalent cohort was 2.3%. The prevalence is 
lower than that previously reported in South Africa ( 6%) but was consistent with that published 
in other study (2.4%)15,94 . The possible reason for this may be due to improved access to HIV 
services leading to reduction in nephropathy attributable to advanced HIV infection.  
 
In the prevalent cohort, predictors associated with development of CKD included lower CD4 
nadir, the use of a TDF based regimen, and low BMI which is consistent with previous 
studies48,63,69. Studies have shown that there is marked racial predilection for development of 
chronic kidney disease in blacks compared to other races35, 36. Evaluation of  racial differences as 
possible risk factor for development of CKD stage 3 or worse  was not conducted because the 
study’s cohort was predominately black (97%). 
 
This study further demonstrated that CKD stage 3 or worse was more prevalent in patients on a 
TDF based regimen then other regimens. This is concordant with other studies which 
demonstrate that tenofovir use is a potential risk factor for renal impairment.   
Studies have shown that patients who concomitantly used tenofovir and a lopinavir boosted 
protease inhibitor had a significant deterioration in kidney function as opposed to those who 
received other regimens such as non-nucleoside reverse transcriptase inhibitors with tenofovir67, 
68,95
. However, this was not demonstrated in this study possibly due to the small number of 
patients (1.4%) that were on a TDF and protease inhibitor based regimen.  
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From this study, it was noted that ESRD was uncommon among patients with CKD stage 3 and 
worse. Of 58 patients with CKD, only 6(10.3%) had CKD stage 5. 
 
4.2 LIMITATION OF THE STUDY  
 
The study had several limitations which include 
 
• It was a retrospective study. 
• Some patients had missing data. 
• Proteinuria was not looked at because it was not recorded in the database. 
 
4.3 CONCLUSION 
 
The doubling of serum creatinine from the baseline or development of ESRD, as the primary end 
point, after initiation of HAART was an uncommon finding in the incident cohort. Renal 
dysfunction, although uncommon, was seen to occur at any time during the course of 
antiretroviral therapy. The overall incidence and prevalence of chronic kidney disease was low, 
supporting the current change in the epidemiology of kidney disease in post HAART era with 
fewer causes of nephropathy due to HIV disease severity. Among patients with renal 
dysfunction, decline in estimated GFR more attributable to traditional risk factors for CKD, TDF 
based regimen and low CD4 count. 
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 Screening for evidence of renal dysfunction among patients on antiretroviral therapy and 
treatment of traditional risks factors for CKD is important for preventing further renal damage.  
 
4.4 Disclosure statement 
There are no conflicts of interest. 
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Appendix 1: Incident cohort data collection sheet  
 
Demographics 
Sex  Male   
Female   
Age in years 
 
<65  
≥65  
 
Race 
Black African  
Other races  
Concurrent medical condition and drug use 
 
BMI(Kg/m2) 
<18.5(underweight)  
18.5to24.9(normal)  
>25.0(overweight)  
Hypertension  
 
Yes   
No  
Nephrotoxic drug use 
 
Yes   
No   
HIV related factors 
CD4  nadir at initiation 
of HAART(cells/uL) 
<200  
≥ 200  
Viral load at initiation  of 
HAART (copies/ml) 
<30,000  
≥ 30,000  
 
HAART Regimen 
TDF based  
TDF+ Lopinavir  
Lopinavir with   
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Other combination 
 Other   
Baseline serum 
creatinine mmol/l 
  
Serum creatinine after 
initiation of HAART 
  
Baseline eGFR   
eGFR after initiation of 
HAART 
  
End point (ESRD or 
doubling of serum 
creatinine from the 
baseline) 
Yes   
No   
Duration in weeks  of 
reaching end point 
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Appendix 2: Prevalent cohort data collection sheet   
 
Demographics 
Sex  
 
Male   
Female   
Age in years 
 
<65  
≥65  
Race 
 
Black African  
Other races  
Concurrent medical condition  
 
 
BMI(Kg/m2) 
<18.5(underweight)  
18.5to24.9(normal)  
>25.0(overweight)  
Renal function ( first and second eGFR  taken at least 3 months apart) 
 
eGFR 
First   
Second    
CKD stage 3 or 
worse 
Yes   
No  
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